Proteins, I.e., More Than 100 Amino Acid Residues Patents (Class 530/350)
  • Patent number: 11325961
    Abstract: To provide a therapy and a diagnosis of cancer or an infection using recognition mechanism of a T-cell receptor.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: May 10, 2022
    Assignee: TOHOKU UNIVERSITY
    Inventor: Koetsu Ogasawara
  • Patent number: 11312944
    Abstract: Compositions comprising modified recombinant polymerizing enzymes are provided, along with nucleic acid molecules encoding the modified polymerizing enzymes. In some aspects, methods of using such polymerizing enzymes to synthesize a nucleic acid molecule or to sequence a nucleic acid template are provided.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: April 26, 2022
    Assignee: Quantum-Si Incorporated
    Inventors: Brian Reed, Mohammad Wadud Bhuiya, Manjula Pandey, Jeremy Lackey, Jonathan M. Rothberg, Thomas Christian
  • Patent number: 11313860
    Abstract: The capabilities of using gold nanoparticle as surface-enhanced Raman scattering (SERS) substrate to obtain cervical smear harvested cells biochemical information for non-invasive cervical precancerous detection were presented in this patent document. A SERS reagent and a platform has been developed and optimized for the generation of a differential spectral fingerprinting for cervical cancer detection. SERS measurements were performed on three group's cervical exfoliated cell samples: one group from patients (n=36) with pathologically confirmed cervical cancer and another group with high-grade squamous intraepithelial lesion (HSIL) (n=41) and the last group from healthy volunteers (control subjects, n=47).
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: April 26, 2022
    Assignee: Council of Scientific & Industrial Research
    Inventors: Kaustabh Kumar Maiti, Varsha Karunakaran, Kunjuraman Sujathan
  • Patent number: 11299734
    Abstract: The present invention relates to the discovery of an effective treatment for a variety of gain-of-function diseases, in particular, Huntington's disease (HD). The present invention utilizes RNA Interference technology (RNAi) against polymorphic regions in the genes encoding various gain-of-function mutant proteins resulting in an effective treatment for the gain-of-function disease.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: April 12, 2022
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Neil Aronin, Phillip D. Zamore
  • Patent number: 11293027
    Abstract: The present invention provides a recombinant Bacillus subtilis with improved 2?-fucosyllactose production, and a construction method thereof. In the present invention, a strain capable of efficiently synthesizing 2?-fucosyllactose is obtained by the fusion expression of the fucosyltransferase gene and the L-fucokinase/guanosine 5?-diphosphate-L-fucose pyrophosphorylase gene in Bacillus subtilis BSGL-FF, the fermentation supernatant of which comprises a cumulative amount of 2?-fucosyllactose as high as 1.62 g/L, which is 55% higher than the amount achieved with the control strain. The construction method of the recombinant Bacillus subtilis of the present invention is simple, and convenient to use, and thus has good application prospects.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: April 5, 2022
    Assignee: JIANGNAN UNIVERSITY
    Inventors: Long Liu, Jian Chen, Xueqin Lv, Guocheng Du, Jianghua Li, Jieying Deng, Ke Liu
  • Patent number: 11279752
    Abstract: Provided herein are recombinant masking proteins and recombinant ligand proteins useful in treating cancer, neurodegenerative disease, and cardiovascular disease. The recombinant masking proteins provided herein may, inter alia, be used as non-covalent masks of antagonists of, for example, cellular growth factors (e.g., TNF) or cell surface proteins (e.g., CTLA-4).
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: March 22, 2022
    Assignees: CITY OF HOPE, THOMAS JEFFERSON UNIVERSITY
    Inventors: John C. Williams, Ulrich Rodeck, Kurt Jenkins
  • Patent number: 11274144
    Abstract: This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: March 15, 2022
    Assignee: Research Institute at Nationwide Children's Hospital
    Inventors: Steven D. Goodman, Lauren O. Bakaletz
  • Patent number: 11273206
    Abstract: Provided herein are new compositions and methods to target pharmaceutical agents to pathological areas by utilizing bifunctional fusion polymers or nanoparticles. These fusion polymers and nanoparticles contain two or more domains: (i) sequences that bind to exposed collagenous (XC-) proteins present in pathological areas, including cancerous lesions and (ii) domains that bind to pharmaceutical agents. The drug-binding functionality of these fusion polymers and nanoparticles is based on high-affinity, non-covalent interactions.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: March 15, 2022
    Assignee: Counterpoint Biomedica LLC
    Inventors: Frederick L. Hall, Erlinda M. Gordon
  • Patent number: 11267863
    Abstract: Disclosed are a novel N-terminal fusion partner, a fusion polypeptide including the fusion partner and a target polypeptide, and a method for producing a target polypeptide using the same. The novel fusion partner can enhance the yield of a target polypeptide (recombinant polypeptide) compared to the conventional fusion partners. Using the novel fusion partner is particularly beneficial in producing a target polypeptide having a relatively low molecular weight and an easily degradable amino terminus based on genetic recombination technologies. Further, the novel fusion polypeptide including the fusion partner can be expressed as inclusion bodies in a host cell and protected against proteases or the like in a host cell, which makes the target polypeptide produced stably. Therefore, in comparison to the conventional fusion partners, the novel fusion partner can be used to provide a method for producing a recombinant peptide with improved stability and yield.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: March 8, 2022
    Assignee: PEPGENE INC.
    Inventor: Sung Gun Kim
  • Patent number: 11260098
    Abstract: An appetite-suppressing composition is characterized by comprising, as an active component, the liquid component derived from Indian mulberry (Morinda citrifolia). The solution is the liquid component extracted from fermented Indian mulberry fruits, which includes the residual liquid containing the >3,000 component and the filtrated liquid containing the <3,000 component. Considerably, provided is the food that possesses the appetite-suppressing composition without showing the non-specific effect on appetite suppression.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: March 1, 2022
    Inventor: Masatomo Mori
  • Patent number: 11255862
    Abstract: The present invention refers to osteomodulin (OMD) protein or fragment of osteomodulin (OMD) protein for use in the prognosis and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis of mammals, preferably human individuals. The present invention further refers to a method for prognosis and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis, comprising the following steps: i) measuring osteomodulin (OMD) protein or a fragment or fragments of osteomodulin (OMD) protein in samples of body fluids of mammalian individuals, preferably human serum samples; ii) judging that decreased levels of osteomodulin (OMD) protein or of said fragment(s) compared to levels in body fluids, preferably serum, of healthy individuals indicate onset of osteoarthritis and/or subchondral bone sclerosis.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: February 22, 2022
    Assignee: UNIVERSITÉ DE LIÈGE
    Inventors: Yves Henrotin, Christelle Sanchez, Edwin De Pauw, Gabriel Mazzucchelli
  • Patent number: 11254727
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: February 22, 2022
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • Patent number: 11254712
    Abstract: Disclosed are chimeric polypeptides based on viral membrane fusion proteins. More particularly, the present invention discloses chimeric polypeptides that comprise a virion surface exposed portion of a viral fusion protein and a heterologous structure-stabilizing moiety, and to complexes of those chimeric polypeptides. The present invention also discloses the use of these complexes in compositions and methods for eliciting an immune response to a fusion protein of an enveloped virus, or complex of the fusion protein, and/or for treating or preventing an enveloped virus infection. The present invention further discloses the use of the heterologous structure-stabilizing moiety for oligomerizing heterologous molecules of interest.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: February 22, 2022
    Assignee: The University of Queensland
    Inventors: Keith Joseph Chappell, Daniel Watterson, Paul Robert Young
  • Patent number: 11248202
    Abstract: A cell observation device is cell observation device for observing a cell held by a microplate having a well holding a sample including the cell and includes a microplate holder for holding the microplate thereon, an electrical stimulation unit including an electrode pair including a first electrode and a second electrode, and a position controller for controlling a position of the electrical stimulation unit in a state in which the first electrode is disposed closer to the center of the well than the second electrode when the electrode pair is disposed in the well of the microplate. The tip of the first electrode extends more than the tip of the second electrode.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: February 15, 2022
    Assignee: HAMAMATSU PHOTONICS K.K.
    Inventors: Natsumi Saito, Taira Ito, Takuji Kataoka
  • Patent number: 11242365
    Abstract: The present invention provides FOXM1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: February 8, 2022
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Sachiko Yamashita, Tetsuro Hikichi
  • Patent number: 11236145
    Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: February 1, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Leonie Alten, Dominik Maurer, Sebastian Bunk, Claudia Wagner, Mathias Ferber
  • Patent number: 11225689
    Abstract: The present invention provides for methods of identifying cell types and cell subtypes from a biological sample or population of target cells. The methods further provide for determining cell type or cell subtype signatures. The method further provides for bipolar cell subtypes and markers and cell signatures thereof.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: January 18, 2022
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Karthik Shekhar, Sylvain Lapan, Irene Whitney, Evan Macosko, Steven McCarroll, Constance Cepko, Aviv Regev, Joshua Sanes
  • Patent number: 11214606
    Abstract: Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the Lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: January 4, 2022
    Assignee: Applied Molecular Transport Inc.
    Inventors: Randall J. Mrsny, Tahir Mahmood, Amir Porat, Charles Olson, Sally Postlethwaite, Weijun Feng, Khushdeep Mangat
  • Patent number: 11208466
    Abstract: A cytochrome b-glucose dehydrogenase fusion protein having modified electron transfer properties, and a glucose measurement method and measuring kit using the cytochrome b-glucose dehydrogenase fusion protein are provided. Provided are a cytochrome b-glucose dehydrogenase fusion protein in which glucose dehydrogenase having homology with SEQ ID NO: 1 or SEQ ID NO: 4 and cytochrome b are linked together, as well as a glucose measurement method, a measurement reagent kit and a sensor using the cytochrome b-glucose dehydrogenase fusion protein. The cytochrome b-glucose dehydrogenase fusion protein of the present invention has modified electron transfer properties, and can be used for measuring glucose in the presence of a free-form mediator in reduced concentration or in the absence of a free-form mediator, and can be used, for example, in continuous glucose monitoring.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: December 28, 2021
    Assignee: KIKKOMAN CORPORATION
    Inventors: Yosuke Masakari, Seiichi Hara
  • Patent number: 11197820
    Abstract: Provided herein are methods and composition for trans-tympanic membrane delivery of therapeutic agents such as antimicrobial agents, anti-inflammatory agents, and anti-biofilm agents to the middle ear for rapid, localized treatment and prevention of diseases and conditions associated with a middle ear infection. In particular, provided herein are cationic, anionic, and polymer-based nanoparticles that provide a platform for delivery of therapeutic cargo, as well as cationic, anionic, and polymer-based nanoparticles compositions for rapid, localized delivery of therapeutic agents to the middle ear.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: December 14, 2021
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: Amit Joshi, Joseph Edward Kerschner, Wenzhou Hong, Gayatri Sharma
  • Patent number: 11185594
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the formula: L1-L2-LP-NH—(CH2)n1-La-Lb-Lc or -L1-L2-LP- wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the terminal Lc or LP with the nitrogen atom of the amino group at position 1 as the connecting position.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: November 30, 2021
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroyuki Naito, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yusuke Ogitani, Yuki Abe
  • Patent number: 11179441
    Abstract: Provided are ciliary neurotrophic factor receptor (CNTFR) ligands. In certain aspects, a CNTFR ligand of the present disclosure exhibits increased affinity for CNTFR relative to the corresponding wild-type CNTFR ligand. In certain aspects, a CNTFR ligand of the present disclosure results in reduced binding affinity of glycoprotein 130 (gp130), leukemia inhibitory factor receptor (LIFR), or both, for a complex including the CNTFR ligand and CNTFR, relative to the binding affinity for a complex including the corresponding wild-type CNTFR ligand and CNTFR. In certain aspects, a CNTFR ligand of the present disclosure has both of the aforementioned properties. Also provided are pharmaceutical compositions including the CNTFR ligands, as well as methods of using the CNTFR ligands.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: November 23, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jun Woo Kim, Jennifer R. Cochran, Eric Alejandro Sweet
  • Patent number: 11168119
    Abstract: The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure further shows the human lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells overexpressing MHC class II. The present disclosure also concerns methods of making LAG-3 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: November 9, 2021
    Assignee: PIERIS PHARMACEUTICALS GMBH
    Inventors: Christine Rothe, Shane Olwill, Andrea Allersdorfer, Timo Eichner, Rachida Siham Bel Aiba, Marina Pavlidou
  • Patent number: 11154041
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL4R and/or IL4, and methods of use thereof.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: October 26, 2021
    Assignees: Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Biocytogen JiangSu Co., Ltd.
    Inventors: Yuelei Shen, Yanan Guo, Yang Bai, Rui Huang, Xiaofei Zhou, Chengzhang Shang, Meiling Zhang, Jiawei Yao, Chaoshe Guo
  • Patent number: 11155793
    Abstract: The present invention relates to the field of genetic engineering, particularly to phytase variant YeAPPA having improved pepsin resistance and acid resistance, and increased catalytic efficiency, by substituting Leucine at the 162th site of the sequence set forth in SEQ ID NO.1 with glycine or proline or substituting glutamic acid at the 230th site of the sequence set forth in SEQ ID NO.1 with glycine, proline or arginine, in the benefit of the development of economical feed enzyme industry.
    Type: Grant
    Filed: January 15, 2018
    Date of Patent: October 26, 2021
    Inventors: Canfang Niu, Peilong Yang, Bin Yao, Yangyang Li, Yongkai Du, Huiying Luo, Huoqing Huang, Yaru Wang
  • Patent number: 11141461
    Abstract: The present invention is in the field of medicine and provides means and methods for the treatment, prevention or amelioration of osteoarthritis. More in particular, it provides a peptide for use in the treatment, amelioration or prevention of osteoarthritis, wherein the peptide is between 12 and 28 amino acids in length and comprises an amino acid sequence according to SEQ ID NO: 16 or a variant thereof according to formula 2, wherein the amino acid sequence of said peptide is comprised in SEQ ID NO: 34 or a variant thereof according to formula 1.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: October 12, 2021
    Assignee: Chondropeptix
    Inventors: Tim Johannes Maria Welting, Marjolein Maria Johanna Caron
  • Patent number: 11129882
    Abstract: The invention relates to a virus like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, asthma, and/or allergy diseases/disorders.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: September 28, 2021
    Assignee: University of Copenhagen
    Inventors: Adam Frederik Sander Bertelsen, Ali Salanti, Thor Theander, Susan Thrane, Christoph Mikkel Janitzek, Mette Ørskov, Morten Agertoug Nielsen
  • Patent number: 11124826
    Abstract: Provided herein are methods and compositions to determine the efficacy of a nucleic acid pre-amplification reaction.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: September 21, 2021
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Yanhong Kong, Steven Okino
  • Patent number: 11116833
    Abstract: Embodiments relate to expressing or overexpressing P-selectin glycoprotein ligand-1 (PSGL-1) in human immunodeficiency virus (HIV) producing cells; isolating HIV particles from the HIV producing cells; and preparing the isolated HIV particles as a HIV vaccine. Embodiments relate to a HIV vaccine comprising live attenuated, inactivated, or non-infectious HIV particles. Embodiments relate to systems performing a method comprising administering a vaccine comprising live attenuated, inactivated, or non-infectious HIV particles to a subject in need of the vaccine; and treating or preventing one or more disease states in the subject resulting from HIV infection.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: September 14, 2021
    Assignee: George Mason University
    Inventors: Yuntao Wu, Yajing Fu, Deemah Dabbagh, Zheng Zhou
  • Patent number: 11103474
    Abstract: The present invention relates to a pharmaceutical formulation suitable for parenteral administration containing carglumic acid and a buffering agent having a pKa from 5.5 to 9.0 at 25° C.; according to an embodiment, the buffering agent may have a pKa from 7.5 to 8.5, preferably a pKa of about 8.07, such as trometamol. The formulation may also contain at least one bulking agent, such as mannitol. The invention also includes a method for manufacturing a lyophilised sterile formulation by freeze-drying a water solution containing carglumic acid, a buffering agent having a pKa from 5.5 to 9.0 at 25° C., preferably from 7.5 to 8.5, and optionally a bulking agent to obtain a freeze-dried powder.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: August 31, 2021
    Assignee: RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
    Inventors: Fabio Berlati, Sergio Menegon, Pierluigi Farina, Diego Provvedini, Marco Barchielli, Alberto Mattei
  • Patent number: 11090396
    Abstract: Compounds containing TRPV6-binding peptides and their use in the detection and diagnosis of cancer are described. Also described are methods for detecting and staging cancer that use the compounds of the invention. Compounds containing TRPV6-binding peptides are useful for the delivery of diagnostic and therapeutic agents to cells or tumors that express TRPV6.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: August 17, 2021
    Assignee: Soricimed Biopharma Inc.
    Inventor: John M. Stewart
  • Patent number: 11083808
    Abstract: An improved pasteurisation protocol for pasteurising microbial cells is disclosed. The protocol has three stages, a first heating stage, a second plateau stage at which the cells are held at a (maximum and) constant temperature, and a third cooling stage. Both the heating and the cooling stages are rapid, with the temperature of the cells passing through 40 to 80° C. in no more than 30 minutes in the heating stage. The heating rate is at least 0.5° C./minute and during cooling is at least ?0.5° C./minute. The plateau maximum temperature is from 70 to 85° C. By plotting the pasteurisation protocol on a time (t, minutes) versus temperature (T, ° C.) graph, one obtains a trapezium having an area less than 13,000° C. minute. Not only does this result in a smaller energy input (and so a reduction in costs), but a better quality (and less oxidised) oil results having a peroxide value (POV) of less than 1.5 and an anisidine value (AnV) of less than 1.0.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: August 10, 2021
    Assignee: DSM IP Assets B.V.
    Inventors: Albert Schaap, Daniel Veroeijen
  • Patent number: 11085034
    Abstract: The present invention relates to an enzyme complex in which a heme polymerase and a heme ligase are linked to each other via the dockerin module of cellulase, and to a method for producing a hemozoin using the same. The enzyme complex according to the present invention can polymerize heme with higher efficiency than conventional enzymes, and thus can more efficiently produce hemozoin, a conductive biopolymer.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: August 10, 2021
    Assignee: Korea University Research and Business Foundation
    Inventors: Sung Ok Han, Jeong-Eun Hyeon, Young-jin Ko
  • Patent number: 11076615
    Abstract: Disclosed herein are methods and compositions including casein, and methods for making these compositions.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: August 3, 2021
    Assignee: Perfect Day, Inc.
    Inventors: Ryan Pandya, Perumal Gandhi, Shaowen Ji, Derek Beauchamp, Louis Hom
  • Patent number: 11078519
    Abstract: Disclosed herein are methods for determining the amount or activity of one or more luciferases and methods for measuring the luminescent signal generated by one or more luciferases in a sample, the methods comprising incubating the sample with a reactive substrate(s) of the luciferase(s) to be analysed and a reducing agent to inactivate a first luciferase, wherein the first luciferase, in its native form, is a secreted luciferase.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: August 3, 2021
    Assignee: GENE STREAM PTY LTD.
    Inventors: Marco Peter Leu, John Michael Daly
  • Patent number: 11058129
    Abstract: The present invention relates to methods of releasing galactose from legumes using polypeptides having alpha-galactosidase activity. The invention also relates to polypeptides having alpha-galactosidase activity, polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of 5 producing the polypeptides. The invention also relates to compositions comprising the polypeptides of the invention and the use of the polypeptides in animal feed.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: July 13, 2021
    Assignee: Novozymes A/S
    Inventors: Lone Carstensen, Nikolaj Spodsberg, Morten Gjermansen, Jesper Salomon, Kristian Bertel Roemer M. Krogh, Eduardo Antonio Della Pia
  • Patent number: 11053301
    Abstract: Described herein are methods and compositions relating to nanodiscs, e.g., phospholipid bilayers with a proteinaceous belt or border. Further provided herein are loopable membrane scaffold proteins, e.g., for forming nanodiscs.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: July 6, 2021
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gerhard Wagner, Mahmoud Nasr
  • Patent number: 11046733
    Abstract: The present invention relates to compositions comprising CpG rich DNA from Pseudomonas aeruginosa. The compositions optionally comprise a cupredoxin. The present invention includes specific CpG DNAs from Pseudomonas aeruginosa that are useful for treating cancer and other conditions in patients. These compositions are optionally in a pharmaceutically acceptable carrier and also optionally comprise a cupredoxin. The present invention further relates to methods to express proteins near cancer cells. These methods may be used to express therapeutic or diagnostic proteins near cancer cells in a patient suffering from cancer or other conditions, and can also be used for diagnosing cancer in a patient. This method uses the gene for azurin from P. aeruginosa as an expression system for azurin or heterologous proteins in P. aeruginosa or heterologous cells.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: June 29, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Tapas Das Gupta, Ananda Chakrabarty
  • Patent number: 11040090
    Abstract: Present invention provides a stable pharmaceutical composition comprising botulinum neurotoxin, anesthetic in a buffer. Present invention also provides a process for the preparation of the stable pharmaceutical composition. The botulinum neurotoxin is stabilized by the formation of complex between the toxin and anesthetic. The present invention further provides a method for treating wrinkles using the said pharmaceutical composition.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: June 22, 2021
    Assignee: Prime Bio, Inc
    Inventor: Bal Ram Singh
  • Patent number: 11028408
    Abstract: Disclosed are compositions and methods comprising one or more recombinant influenza viruses. Recombinant influenza viruses with mutated polymerases and/or rearranged genomes are disclosed. Constructs comprising different influenza nucleic acid sequences are also provided. Methods of inducing protecting immunity with the recombinant influenza viruses are disclosed. Also disclosed are methods of plasmid-free production of influenza virus comprising amplicons comprising one or more of influenza genes.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: June 8, 2021
    Assignee: UNIVERSITY OF MARYLAND, COLLEGE PARK
    Inventors: Daniel R. Perez, Hongjun Chen, Yibin Cai, Lindomar Jose Pena, Matthew Angel
  • Patent number: 10995155
    Abstract: The present disclosure provides a composite of (a) oxidized cellulose comprising at least one carboxyl and (b) at least one component selected from a diamine, a diol, or mixture thereof. This disclosure further relates to methods of making such composite materials and suitable uses thereof, including in fibers, fabrics, textiles, films, fillers, packaging materials, plastics, etc.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: May 4, 2021
    Assignee: GP CELLULOSE GMBH
    Inventors: Arthur J. Nonni, Charles E. Courchene, Christopher M. Slone, Blair R. Carter, Anna L. Wells, James M. Keough
  • Patent number: 10980826
    Abstract: The present application provides a pharmaceutical composition for treating and/or preventing a cancer comprising, as an active ingredient, a polynucleotide derived from miRNA associated with the cancer, a combination drug of the pharmaceutical composition and another antitumor agent, and a method for treating or preventing a cancer in a subject having the cancer using the pharmaceutical composition or the combination drug.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: April 20, 2021
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Atsuko Miyano, Hiroko Sudo, Aiko Takayama, Taiga Arai
  • Patent number: 10981959
    Abstract: Compositions comprising a mixture of proteins derived from MaSP, nucleic acids encoding same and method for the preparation of synthetic dragline spider silk are provided. The compositions of the invention comprise a mixture of proteins of differing molecular weight, wherein each protein of said mixture comprises, independently, multiple repeats of a repetitive region of a MaSP (major ampullate spidroin) protein or a functional homolog, variant, derivative or fragment thereof.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: April 20, 2021
    Assignee: SEEVIX MATERIAL SCIENCES LTD.
    Inventors: Shmulik Ittah, Meni Shimel, Uri Gat
  • Patent number: 10961287
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: March 30, 2021
    Assignee: Amunix Pharmaceuticals, Inc
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
  • Patent number: 10921330
    Abstract: CSF diagnostic in vitro method for the diagnosis of dementias and neuroinflammatory diseases, in which a determination of the procalcitonin immunoreactivity (PCT immunoreactivity) is carried out in a sample of cerebrospinal fluid (CSF) of a patient who is suffering from a dementia or neuroinflammatory disease or is suspected of suffering from such a disease. Conclusions about the presence, the course, the severity or the success of a treatment of the dementia or neuroinflammatory disease are drawn from a measured PCT immunoreactivity which is above a threshold value typical for healthy individuals.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: February 16, 2021
    Assignee: B.R.A.H.M.S GMBH
    Inventors: Andreas Bergmann, Andrea Sparwaβer, Harald Hampel
  • Patent number: 10907219
    Abstract: This disclosure describes compositions and methods that involve a first modular component and a second modular component. The first modular component includes a first target molecule coupled to a first dimerizing moiety. The second modular component includes a second target molecule coupled to a second dimerizing moiety. The first dimerizing moiety dimerizes with the second dimerizing moiety when the first dimerizing moiety binds a chemical induced proximity (CIP) inducer.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: February 2, 2021
    Assignee: UNM Rainforest Innovations
    Inventors: Fu-Sen Liang, Wei Wang
  • Patent number: 10907173
    Abstract: Compositions having pesticidal activity and methods for their use are provided. Compositions include isolated and recombinant polypeptide sequences having pesticidal activity, recombinant and synthetic nucleic acid molecules encoding the pesticidal polypeptides, DNA constructs comprising the nucleic acid molecules, vectors comprising the nucleic acid molecules, host cells comprising the vectors, and antibodies to the pesticidal polypeptides. Nucleotide sequences encoding the polypeptides provided herein can be used in DNA constructs or expression cassettes for transformation and expression in organisms of interest. The compositions and methods provided herein are useful for the production of organisms with enhanced pest resistance or tolerance. Transgenic plants and seeds comprising a nucleotide sequence that encodes a pesticidal protein of the invention are also provided. Methods are provided for producing the polypeptides disclosed herein, and for using those polypeptides for controlling a pest.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: February 2, 2021
    Assignee: AgBiome, Inc.
    Inventors: Kira Bulazel Roberts, Rebecca E. Thayer, Jessica Parks
  • Patent number: 10900968
    Abstract: A method of prognosing and predicting breast cancer recurrence stratifies early stage ER+/PR+ and Her2? breast cancer patients with invasive ductal/lobular carcinoma of the breast into low risk or high risk for breast cancer recurrence by employing an IHC based assay which assesses or measures expression of a combination of 5 biomarkers and by employing a histopathological analysis which assesses 3 clinical prognostic parameters.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: January 26, 2021
    Assignee: ONCOSTEM PTE. LTD.
    Inventors: Manjiri Bakre, Charusheila Ramkumar
  • Patent number: 10888609
    Abstract: The present invention provides in certain embodiments compositions comprising at least one CD200 inhibitor, and methods of reversing or modulating immune suppression in a patient having a disease or disorder arising from abnormal cell growth, function or behavior, which method comprises administering to a patient in need thereof a CD200 inhibitor composition.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 12, 2021
    Assignee: Regents of the University of Minnesota
    Inventor: Michael Olin
  • Patent number: 10870925
    Abstract: Protein arrays and their use to assay, in a parallel fashion, the protein products of highly homologous or related DNA coding sequences and described. By highly homologous or related it is meant those DNA coding sequences which share a common sequence and which differ only by one or more naturally occurring mutations such as single nucleotide polymorphisms, deletions or insertions, or those sequences which are considered to be haplotypes. Such highly homologous or related DNA coding sequences are generally naturally occurring variants of the same gene. Arrays according to the invention have two or more individual proteins deposited in a spatially defined pattern on a surface in a form whereby a property such as an activity or function of the proteins can be investigated or assayed in parallel by interrogation of the array.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: December 22, 2020
    Assignee: SENGENICS CORPORATION PTE LTD
    Inventors: Jonathan Mark Boutell, Benjamin Leslie James Godber, Darren James Hart, Jonathan Michael Blackburn